Celcuity

76 articles about Celcuity

• Celcuity Announces Proposed Public Offering of Common Stock

  2/22/2021

  MINNEAPOLIS, MN / ACCESSWIRE / February 22, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3 rd generation diagnostics and expanded therapeutic options for cancer patients, today announced that it has commenced an underwritten public offering of $20 million of shares of common stock. In connection with this offering, Celcuity expects to grant the underwriter of the offering a 30-day option to purchase up to an add

• Celcuity Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

  2/16/2021

  Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the fourth quarter and year ended December 31, 2020

• Celcuity Inc. Schedules Release of Fourth Quarter and Fiscal Year 2020 Financial Results and Conference Call

  2/1/2021

  Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the fourth quarter and fiscal year 2020 after the stock market close on Tuesday, February 16, 2021

• Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen

  1/27/2021

  Celcuity Announces Breast Cancer Clinical Trial Collaboration with Sarah Cannon and Pfizer to Study New Drug Regimen - Trial will evaluate the efficacy and safety of Pfizer’s targeted therapies, VIZIMPRO ® and XALKORI ® , in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test

• Celcuity to Present at the B. Riley Oncology Investor Conference

  1/19/2021

  Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology company utilizing its 3 rd generation companion diagnostics to identify new targeted therapeutic options for cancer patients, announced today that Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity, will present at the B. Riley Oncology Investor Conference to be held January 20-21, 2021. Mr. Sullivan will present an overview of Celc

• Celcuity Announces Clinical Trial Collaboration with Massachusetts General Hospital and Puma Biotechnology

  12/23/2020

  Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HER2-negative breast cancer patients selected by the CELsignia® Test

• Celcuity Reports Third Quarter 2020 Financial Results and Recent Business Highlights

  11/9/2020

  Celcuity Inc., a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the third quarter ended September 30, 2020 and summarized recent business progress.

• Celcuity Inc. Schedules Release of Third Quarter 2020 Financial Results and Conference Call

  10/26/2020

  Celcuity Inc. (Nasdaq:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the third quarter 2020 after the stock market close on Monday, November 9, 2020.

• Celcuity to Present at the LD Micro 500 Investor Conference

  8/27/2020

  Celcuity Inc. announced today that management will present at the LD 500 Investor Conference, hosted by LD Micro and taking place virtually September 1 - 4, 2020.

• Celcuity Reports Second Quarter 2020 Financial Results and Recent Business Highlights

  8/10/2020

  Celcuity Inc. announced financial results for the second quarter ended June 30, 2020 and summarized recent business progress.

• Celcuity Inc. Schedules Release of Second Quarter 2020 Financial Results and Conference Call

  7/24/2020

  Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the second quarter 2020 after the stock market close on Monday, August 10, 2020. Management will host a teleconference the same day at 4:30 p.m. Eastern Time (ET) to discuss the results.

• Conference Call

  7/1/2020

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020 at 1:00 pm Eastern Time.

• Celcuity Inc. announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020

  7/1/2020

  Celcuity Inc. announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020 at 1:00 pm Eastern Time.

• Celcuity Announces Appointment of Eric Lindquist as Chief Business Officer

  9/9/2019

  Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and developing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced that Eric Lindquist joined the company as its Chief Business Officer.

• Celcuity Announces Closing Of Initial Public Offering

  9/25/2017

• Celcuity Announces Pricing Of Initial Public Offering

  9/20/2017